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Summary After more than 20 years of clinical experience in children, bone-anchored hearing
aids, essentially BAHA®, have become the standard treatment for conductive or mixed hearing
loss. Based on a general review of the literature and the authors’ own experience, this article
reviews the use of bone-anchored hearing aids in children. The main indications for bone-
anchored hearing aids are a minimum age of 5 years at the time of implantation and/or cortical
bone thickness≥ 3mm. Fixture loss is observed in 40% of children under the age of 5 years versus
8% for children aged 5 to 10 years and 1% for children over the age of 10 years, i.e. identical to
the rate observed in adults. Skin complications are similar to those observed in adults and must
be prevented by parental education and regular follow-up. Surgery is generally performed in two
stages or as a one-stage procedure for ﬁxtures≥ 4mm. The functional success rate, correlated
with medium- and long-term use of BAHA® is about 96%. BAHA® may be indicated in children
with profound unilateral hearing loss following a trial period wearing a BAHA® headband for
several weeks with the child’s active participation. Sequential bilateral implantation requires
complementary investigations and appears to provide improved perception in noise. This type of
hearing aid provides an improvement of the quality of life of children with bilateral conductive
and/or mixed hearing loss which should be further improved as a result of recent technical
developments.
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Introduction
The ﬁrst bone-anchored hearing aid (BAHA®) was implanted
in an adult in Sweden in 1977 [1]. This rehabilitation tech-
nique for conductive and mixed hearing loss then became
commercially available in 1987 [2] and was used for the ﬁrst
time in France by Manach in the same year [3].
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Since then, this technique has gradually become a
aluable alternative to other bone conduction (BC) hear-
ng aids because of a better gain in the high frequency
ange with less distortion, improved comfort and the pos-
ibility of bilateral implantation. This technique consists of
simple, reversible surgical procedure, not exposing the
atient to any risk of additional hearing loss. In adults,
AHA® surgery is performed as a one-stage procedure under
ocal anaesthesia with few complications [4]. However, in
hildren, this surgery is usually performed as a two-stage
rocedure under general anaesthesia on thinner cranial cor-
ical bone and in medically more complex patients. Due to
he increased risk of skin complications, ﬁxture loss and for
served.
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Table 1 Holgers classiﬁcation.
Grade 0 Reaction-free skin around the abutment
Grade 1 Redness with slight swelling around the
abutment
Grade 2 Redness, moistness and moderate swelling
Grade 3 Redness, moistness, and moderate swelling
with tissue granulation around the abutment
Grade 4 Overt signs of infection resulting in removal of
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cigure 1 The three components of the BAHA® (screw, abut-
ent and sound processor).
osmetic reasons, healthcare professionals as well as chil-
ren and their parents often consider BAHA® to be a less
ttractive alternative than in adults.
Based on a general review of the literature and our own
xperience, we have reviewed the place of bone-anchored
earing aids in children.
rinciples of functioning of BAHA®
he BAHA® is an implantable system comprising three
arts. An osteointegrated titanium ﬁxture (screw) sur-
ically implanted in the cortex of the temporoparietal
one behind and above the external ear generates a
requency-dependent elastic deformity of the bone cortex.
cone-shaped, percutaneous titanium abutment attached
o the implant transmits vibrations to the implant. An exter-
al sound processor transforms sound into vibrations of
ariable intensity transmitted from the percutaneous abut-
ent to the osteointegrated implant (Fig. 1).
ndications
AHA® is indicated in cases of conductive and/or mixed
earing loss in which middle ear surgery cannot be per-
ormed and in which conventional air or bone conducting
earing aids are ineffective or impossible. Severe unilateral
ensorineural hearing loss also constitutes an indication
or BAHA® to restore binaural hearing, depending on the
atient’s needs [5]. Audiometric criteria for BAHA® implan-
ation are deﬁned by BC thresholds (measured at 0.5, 1,
and 3 kHz), which are also used to select the type of
earing aid. A BAHA® Divino or BAHA® BP100 can be used
or BC thresholds≤ 45 dB HL, a BAHA® Intenso can be pro-
®osed for BC thresholds≤ 55 dB HL, and a BAHA Cordelle
I is indicated for BC thresholds≤ 65 dB HL with speech dis-
rimination by BC≥ 60%. Bilateral BAHA® is indicated when
he right BC is equal to the left BC with a mean maximum
p
o
sthe implant
ifference < 10 dB. BAHA® is indicated for unilateral cophosis
hen BC thresholds of the healthy ear are≤ 20 dB.
Indications related to the minimum age of implantation
ary from one country to another with an age greater than
r equal to 5 years in the USA [6] and Canada [7], while, in
rance, age is taken into account indirectly by measuring
ortical thickness (≥ 3mm).
omplications
he main short-term, medium-term and long-term post-
perative complications consist of ﬁxture loss and skin
omplications.
The Birmingham team [8] reported a retrospective review
f their experience between 1992 and 2007, based on 182
hildren (mean age: 7 years, range: 2—16 years), including
5 children under the age of 5 years in whom 2-stage surgery
as performed (96% cases). The ﬁxture loss rate in the over-
ll population of implanted children was 14% (32 ﬁxtures lost
ver a period of 15 years). However, in the group of children
nder the age of 5 years, the ﬁxture loss rate was 71% and
ven 100% when a 3mm screw was used. In their review,
ublished in 2009, McDermott and Sheehan reported a mean
xture loss rate of about 40% for children under the age of
years, 8% for children between the ages of 5 and 10 years
nd 1% for children over the age of 10 years [9]. In our expe-
ience of 11 BAHA® ﬁtted in nine children with a mean age
f 12.5 years (± 3.5), all operated by a one-stage procedure
nd with a mean healing time of 3 months, the ﬁxture loss
ate was zero with 4mm screws and 50% for 3mm screws (2
ut of 4 cases).
Adverse skin reactions have been evaluated since 2001
ccording to the Holgers classiﬁcation (Table 1). Studies
ave shown that these complications constitute the main
roblem after BAHA® implantation [4] with a higher mean
ncidence in children than in adults [8,10—12]. These
omplications are due to rubbing of the skin graft against
he abutment. Poor hygiene and insufﬁcient resection of
air follicles during surgery also predispose to skin irritation.
dolescents are also at increased risk of skin complications
ue to the presence of acne. Parents are also often respon-
ible for regular, daily skin care around the abutment, which
ay be difﬁcult to ensure in children with behavioural
isorders and/or mental retardation. These potential skin
omplications must be prevented as far as possible by
arental education and regular follow-up by the surgeon.
Other intraoperative complications are sometimes
bserved, such as bleeding, or exposure of the dura mater or
igmoid sinus. Bleeding is generally controlled by placement
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Figure 3 Intraoperative diagram representing the future
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aFigure 2 Intraoperative view of an implanted screw with a
non-hair-bearing skin ﬂap.
of the ﬁxture. Exposure of the dura mater and/or sigmoid
sinus, observed in almost 70% of paediatric cases, is not con-
sidered to be associated with any particular risks [8]. The
use of neuronavigation systems should help to limit these
complications.
Surgical aspects
Two-stage surgery consists of implantation of the screw in
the mastoid bone followed, after waiting for 4 to 6months
to obtain osteointegration, insertion of the percutaneous
abutment onto the screw. Another interval of several weeks
must be observed before connecting the sound processor to
the abutment. One-stage surgery, performed in adults since
1995, consists of placing the screw and the percutaneous
abutment during the same operation, thereby avoiding the
need for a second operation. In 1996, we proposed this one-
stage technique routinely in adults and children [13] without
observing any increase of the complication rate. Tietze and
Papsin proposed this one-stage surgery for children over the
age of 9 years, when a ﬁxture of at least 4mm is implanted
[2]. Kohan et al. proposed one-stage implantation of two ﬁx-
tures, including a dormant safety ﬁxture, in children after
evaluation of cortical bone thickness by preoperative CT
[11]. According to this author, 3mm and 4mm ﬁxtures were
implanted with good osteointegration. In our experience,
one-stage surgery can be performed in children, but should
not be recommended for ﬁxtures smaller than 4mm in view
of the risks of extrusion [8,14].
The detailed one-stage surgical procedure is similar to
that performed in adults (Fig. 2). The speciﬁc features of
two-stage surgery consist of creation of a ﬂap with reduc-
tion of the subcutaneous tissue during the second operation
at least 3months later. In patients with complete aural
atresia requiring subsequent autologous reconstruction, the
a
l
sAHA® implantation zone situated more than 60mm from the
uture theoretical position of the external auditory canal.
mplantation site must be placed more posteriorly (generally
0 to 65mm) and more superiorly to take into account the
hape of the skin ﬂap (Fig. 3). In order to decrease the surgi-
al time and skin ﬂap complications, some teams perform a
ertical retroauricular incision [15,16]. These various tech-
iques can be performed in children, although no particular
echnique has been shown to be superior to the others.
unctional results
he functional success rate is correlated with medium-
erm and long-term use of the BAHA®. This success rate is
bout 96%. The audiometric improvement varies according
o the initial level of the BC curve, but mean hearing
id thresholds of about 17.5 dB are classically obtained in
atients with conductive hearing loss due to severe apla-
ia [11]. Questionnaire-based evaluations of patients have
lso reported good results in terms of sound quality, ease
f use and quality of life [17,18]. Conditions ensuring these
ood results include multidisciplinary management in pae-
iatric structures, especially for children with associated
raniofacial malformation syndromes.
pecial indications
nilateral hearing loss and BAHA®
he consequences of unilateral hearing loss in children are
urrently correlated with a higher risk of delayed language
cquisition and school difﬁculties, which have led some
uthors to propose hearing aids in these children [19].
In children with congenital unilateral conductive hearing
oss with good sound localization capacities, Kunst et al.
howed that BAHA® did not signiﬁcantly improve hearing
256
Figure 4 Child with a BAHA® headband (prescribed in children
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loo young for BAHA® or as a trial in the presence of unilateral
onductive or sensorineural hearing loss).
n noise [20,21]. Similarly, Priwin et al. in 2007 showed
hat BAHA® did not provide any improvement in sound
ocalization in this type of hearing loss [22,23]. The study by
hristensen et al., published in 2010, used a questionnaire
o evaluate the beneﬁt of BAHA® in children with a mean
ge of 12.6 years (range: 6 to 19 years) presenting profound
nilateral hearing loss, but neither the origin nor the date
f onset of this hearing loss were speciﬁed. In a series of 23
mplanted children, quality of life and perception in noise
ere improved with a complication rate of 17% [24]. On the
asis of this study, this type of indication could be considered
n children following a trial of BAHA® headband for several
eeks with the child’s active participation (Fig. 4).
ilateral BAHA®
he main advantage of bilateral cochlear stimulation is
mprovement of sound localization capacities and speech
nderstanding in noise. The results of bilateral BAHA®
n adults have demonstrated improvement of binaural
apacities [25]. Development of binaural capacities appears
o occur essentially during the ﬁrst 4 years of life, justi-
ying early bilateral implantation in children with hearing
oss [26]. This age-related development validates the pro-
osal of bilateral BAHA® headband during the ﬁrst years of
ife. Few studies on bilateral BAHA® in children over the
ge of 5 years have been published. The questionnaire-based
tudy by Dun, published in 2010 and based on 27 bilat-
rally implanted children between 1996 and 2008 showed
mprovement of sound quality in 70% of cases and a global
®eneﬁt was obtained by permanent bilateral BAHA in 90%
f cases. One or both hearing aids had to be temporarily
urned off because of excessive noise in seven children. Our
xperience of two children treated by sequential implanta-
t
n
t
rS. Roman et al.
ion of bilateral BAHA® indicates that both children used the
wo implants permanently and daily and reported an addi-
ional sense of security in the event of unilateral implant
ailure.
hildren with associated mental retardation
ehabilitation of conductive hearing loss has been success-
ully performed in children with trisomy 21 or learning
ifﬁculties [27,28]. This requires careful preoperative
ssessment of the child’s capacity to accept future daily skin
are around the abutment, the risks of trauma and, in insti-
utionalized children, the possibility of delegation of care
o staff. A conclusive trial of BAHA® headband must also be
ystematically performed to validate this indication.
edicoeconomic aspects
ollowing the CEPP (Pricing committee) opinion dated
4 June 2008, the external part (sound processor), and
he implantable part (abutment and implant) have been
egistered on the list of products and services reimbursed
y French national health insurance, as deﬁned in Arti-
le L. 165-1 of the French Social Security Code by decree
ated 23 October 2009 (Ofﬁcial Journal dated 30 October
009). Consumable items and repairs are reimbursed in the
orm of an annual ﬁxed sum (LPPR 2331043). Prescription
odalities in children are rigorously deﬁned in the Ofﬁcial
ournal article. In practice, the screw and the abutment
re fully reimbursed by French national health insurance,
hile the ﬁxed sum reimbursement of the external hearing
id is 900 Euros. The processor can be replaced after expiry
f the guarantee when processor-related deterioration of
erformances (auditory or nonauditory) is observed.
uture prospects
lternatives to BAHA®
ince 2007, middle ear implants (MEI) have been used for
unctional rehabilitation of conductive and mixed hearing
oss in children. A French team was the ﬁrst to implant a
otally implantable Otologics Carina MEI in a 14-year-old boy
ith bilateral aural atresia in the context of Franceschetti
yndrome [29]. More recently, in June 2009, the indications
or another MEI, the vibrating Med-El, were extended to
nclude conductive and mixed hearing loss in children. Pae-
iatric cases of functional rehabilitation by MEI for unilateral
r bilateral aural atresia, with conductive or mixed hearing
oss have been reported in the literature [30,31].
A new ‘‘closed skin’’ bone-anchored hearing aid called
lpha 1 (M) is currently under evaluation. It is indicated
or conductive or mixed hearing loss with BC thresholds
reater than 45 dB, and for unilateral sensorineural hearing
oss when the normal ear presents a BC threshold greater
han that of the affected ear. The implanted part is a mag-
et contained in a tightly sealed titanium case and soldered
o a ﬁxation plate attached to the bone by four screws. No
esults are yet available in the scientiﬁc literature.
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Innovations for BAHA®
Since 2010, Oticon® has marketed a bone-anchored hear-
ing aid called Ponto. The Ponto-Pro sound processor can
be programmed with automatic multiband adaptive direc-
tionality, trimodal noise management, wind noise reduction
and volume control. No data are currently available on the
results of this system in children.
Cochlear® is developing a new implant, which should sig-
niﬁcantly decrease healing time. This new implant has a
larger diameter and a moderately roughened surface, which
should ensure better primary stability and more rapid and
stronger osteointegration, respectively. The sound proces-
sor ﬁtting time could therefore be individually predicted by
sound frequency analysis, which provides an indirect mea-
sure of implant stability, in the same way as for dental
implants. The frequency of adverse skin reactions around
the abutment should also be decreased due to a watertight
connection between the abutment and the ﬁxture.
Conclusion
Rehabilitation of conductive and mixed hearing loss in chil-
dren by bone-anchored hearing aids is a robust technique
that has been developed for many years with a long-term
functional success rate of more than 96%. However, chil-
dren are exposed to a higher risk of ﬁxture loss and skin
complications than adults. Technical improvements ensuring
greater solidity and more rapid osteointegration are cur-
rently under evaluation. The combination of these various
factors should therefore encourage ENT surgeons to famil-
iarize themselves with this technique so that they can
propose it to children and their families. Alternatives to
bone-anchored hearing aids are also under evaluation.
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